FDA Approval Alert: The Need-to-Know | Repotrectinib in NTRK Gene Fusion-Positive Solid Tumors

In June 2024, the FDA granted accelerated approval to repotrectinib in adult and pediatric patients who are 12 years and older with NTRK gene fusion-positive solid tumors.

Patients 12 years and older with NTRK gene fusion-positive solid tumors may now receive repotrectinib.
FDA OKs Repotrectinib in NTRK Gene Fusion-Positive Solid Tumors
Article
Jun 13, 2024 5:00 PM
Patients 12 years and older with NTRK gene fusion-positive solid tumors may now receive repotrectinib.